# Salecan Suppresses Pancreatic Cancer Progression by Promoting Necroptosis via the RIPK1/MLKL Pathway

**Authors:** Wenya Du, Rong Xu, Pengfei Chen, Jianxia Wen, Luchuanyang Sun, Xianggui Chen

PMC · DOI: 10.3390/nu17193090 · 2025-09-28

## TL;DR

Salecan, a natural polysaccharide, fights pancreatic cancer by triggering cell death through the RIPK1/MLKL pathway without harming normal cells.

## Contribution

Salecan induces necroptosis in pancreatic cancer cells via the RIPK1/MLKL pathway, offering a novel therapeutic strategy.

## Key findings

- Salecan inhibits pancreatic cancer cell proliferation, migration, and invasion.
- Salecan promotes necroptosis rather than apoptosis in pancreatic cancer cells.
- The anti-cancer effects of Salecan are mediated through the RIPK1/MLKL signaling pathway.

## Abstract

Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC) is a malignant tumor and leads to high human malignancy and mortality. Because PDAC is highly drug-resistant and current treatments have adverse reactions, exploring novel approaches for PDAC prevention and therapy is urgently needed. Methods: Antitumor activities of Salecan were evaluated on multiple human pancreatic adenocarcinoma cells in vitro. Cell viability, colony formation, migration and invasion, flow cytometry, caspase-3 activity, qRT-PCR and Western blotting were monitored. RNA-seq was conducted to clarify the mechanism underlying Salecan’s inhibition of pancreatic cancer cell progression. Results: Here we show that Salecan, a naturally occurring polysaccharide of β-glucan, can significantly inhibit pancreatic cancer cell proliferation and exhibit no toxicity in normal cells. We find that Salecan impedes pancreatic cancer cell migration and invasion via the epithelial-to-mesenchymal transition (EMT) pathway. Mechanistically, through RNA sequencing, we reveal that Salecan induces pancreatic cancer cell necroptosis, instead of apoptosis. Moreover, Salecan’s anti-pancreatic cancer bioactivity is attributed to its promotion of the receptor-interacting protein kinase 1 (RIPK1) and mixed lineage kinase-like (MLKL) signaling pathway. Conclusions: Salecan can inhibit pancreatic cancer cell proliferation, migration and invasion in vitro and accelerate cell death by inducing the necroptosis via the MLKL/RIPK1 pathway. These findings identify that Salecan may become a potential functional food component for preventing and treating PDAC.

## Linked entities

- **Genes:** RIPK1 (receptor interacting serine/threonine kinase 1) [NCBI Gene 8737], MLKL (mixed lineage kinase domain like pseudokinase) [NCBI Gene 197259]
- **Diseases:** pancreatic ductal adenocarcinoma (MONDO:0005184), pancreatic cancer (MONDO:0005192)

## Full-text entities

- **Genes:** MLKL (mixed lineage kinase domain like pseudokinase) [NCBI Gene 197259] {aka hMLKL}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, RIPK1 (receptor interacting serine/threonine kinase 1) [NCBI Gene 8737] {aka AIEFL, IMD57, RIP, RIP-1, RIP1}
- **Diseases:** PDAC (MESH:D021441), Pancreatic Cancer (MESH:D010190), malignancy (MESH:D009369), toxicity (MESH:D064420)
- **Chemicals:** Salecan (MESH:C577623), polysaccharide (MESH:D011134), beta-glucan (MESH:D047071)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12525719/full.md

---
Source: https://tomesphere.com/paper/PMC12525719